Topical application of activator protein-1 inhibitor T-5224 suppresses inflammation and improves skin barrier function in a murine atopic dermatitis-like dermatitis
Allergology International · 2024
DOI: 10.1016/j.alit.2023.12.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergology International, 2024. Verfasst von Minori Sasakura und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan. Hauptthemen laut MEDLINE: Azetidines, Benzophenones, Dermatitis, Atopic, Isoxazoles. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi K.K., Maruho, AbbVie.
Abstract (Originalsprache)
BACKGROUND: Selective activator protein (AP)-1 inhibitors are potentially promising therapeutic agents for atopic dermatitis (AD) because AP-1 is an important regulator of skin inflammation. However, few studies have investigated the effect of topical application of AP-1 inhibitors in treating inflammatory skin disorders. METHODS: Immunohistochemistry was conducted to detect phosphorylated AP-1/c-Jun expression of skin lesions in AD patients. In the in vivo study, 1 % T-5224 ointment was topically applied for 8 days to the ears of 2,4 dinitrofluorobenzene challenged AD-like dermatitis model mice. Baricitinib, a conventional therapeutic agent Janus kinase (JAK) inhibitor, was also topically applied. In the in vitro study, human epidermal keratinocytes were treated with T-5224 and stimulated with AD-related cytokines. RESULTS: AP-1/c-Jun was phosphorylated at skin lesions in AD patients. In vivo, topical T-5224 application inhibited ear swelling (P < 0.001), restored filaggrin (Flg) expression (P < 0.01), and generally suppressed immune-related pathways. T-5224 significantly suppressed Il17a and l17f expression, whereas baricitinib did not. Baricitinib suppressed Il4, Il19, Il33 and Ifnb expression, whereas T-5224 did not. Il1a, Il1b, Il23a, Ifna, S100a8, and S100a9 expression was cooperatively downregulated following the combined use of T-5224 and baricitinib. In vitro, T-5224 restored the expression of FLG and loricrin (LOR) (P < 0.05) and suppressed IL33 expression (P < 0.05) without affecting cell viability and cytotoxicity. CONCLUSIONS: Topical T-5224 ameliorates clinical manifestations of AD-like dermatitis in mice. The effect of this inhibitor is amplified via combined use with JAK inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
- Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.
- Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan. Electronic address: zanemori@cc.okayama-u.ac.jp.
Förderung
- Sanofi K.K.
- Maruho
- AbbVie
- Eli Lilly Japan
- Mitsubishi Tanabe Pharma Corporation
Zitieren
APA
Sasakura, M., Urakami, H., Tachibana, K., Ikeda, K., Hasui, K. I., Matsuda, Y., Sunagawa, K., Ennishi, D., Tomida, S., & Morizane, S. (2024). Topical application of activator protein-1 inhibitor T-5224 suppresses inflammation and improves skin barrier function in a murine atopic dermatitis-like dermatitis. Allergology International. https://doi.org/10.1016/j.alit.2023.12.006
Vancouver
Sasakura M, Urakami H, Tachibana K, Ikeda K, Hasui KI, Matsuda Y, et al. Topical application of activator protein-1 inhibitor T-5224 suppresses inflammation and improves skin barrier function in a murine atopic dermatitis-like dermatitis. Allergology International. 2024. doi:10.1016/j.alit.2023.12.006
BibTeX
@article{Sasakura2024,
author = {Sasakura, Minori and Urakami, Hitoshi and Tachibana, Kota and Ikeda, Kenta and Hasui, Ken-Ichi and Matsuda, Yoshihiro and Sunagawa, Ko and Ennishi, Daisuke and Tomida, Shuta and Morizane, Shin},
title = {Topical application of activator protein-1 inhibitor T-5224 suppresses inflammation and improves skin barrier function in a murine atopic dermatitis-like dermatitis},
journal = {Allergology International},
year = {2024},
doi = {10.1016/j.alit.2023.12.006}
}
EUVIMED